NICE and the 2015 General Election

22nd October 2014

NICE and the 2015 General ElectionLeela Barham

What could the forthcoming UK General Election in May 2015 mean for the always evolving National Institute for Health and Care Excellence (NICE)? Leela Barham takes a look at how... Read more

Cutting-edge DNA sequencing to speed diagnostics

21st October 2014

Cutting-edge DNA sequencing to speed diagnosticsQuah Shun Ying and Syamala Ariyanchira

Next Generation Sequencing (NGS) technologies are allowing scientists to sequence DNA faster and expand knowledge of the genetic basis of disease. NGS is showing particular promise in areas where current... Read more

Social enterprises: doing NHS business without the bureaucracy

20th October 2014

Social enterprises: doing NHS business without the bureaucracy Nisha Desai

Nisha Desai, head of medicines management at social enterprise company Provide, speaks to pharmaphorum about how such organisations are benefitting the NHS, prior to her appearance at a major London... Read more

Patients as partners in medicines development – the EUPATI project

17th October 2014

Patients as partners in medicines development – the EUPATI projectJan Geissler

As the head of EUPATI, a consortium of organisations working to put patients at the heart of drug R&D, Jan Geissler has seen first-hand how bringing patients and industry together... Read more


FDA panel backs wider use of Vertex cystic fibrosis drug

22nd October 2014

FDA panel backs wider use of Vertex cystic fibrosis drugStaff reporter

More cystic fibrosis patients in the US should be eligible for treatment with Vertex Pharma's Kalydeco therapy, according to an FDA advisory committee.Yesterday the expert panel voted 13 to two... Read more

J&J to accelerate Ebola vaccine, open to collaboration with rivals

22nd October 2014

J&J to accelerate Ebola vaccine, open to collaboration with rivalsAndrew McConaghie

Johnson & Johnson is to spend $200 million on accelerating development of a new vaccine against the deadly Ebola epidemic.The company's vaccine is one of several currently in development aimed... Read more

Angel investors boost UK bioscience

22nd October 2014

Angel investors boost UK bioscienceLinda Banks

New bioscience companies are set to benefit from greater access to angel backing thanks to an initiative to bring fresh investors into life sciences.Angels in MedCity, launched by MedCity, London... Read more

AbbVie hits out at US Treasury as Shire bid dies

21st October 2014

AbbVie hits out at US Treasury as Shire bid dies Linda Banks

Following AbbVie's recommendation to its shareholders to vote against the takeover of Shire last week, Shire's board has agreed to terminate the Cooperation Agreement and release AbbVie from its obligations... Read more

Audio & Video

Live debate Oct 29th - Managing diabetes…


Non-adherence to self-management regimens in diabetes is globally a widespread, costly and ultimately life threatening issue. 

Reasons for non-adherence are complex... View more

Live webinar: Is pharma brand marketing …

Kantar Health webinar

While pharma observers speculate on the death of outdated drug discovery and sales models, some critical wounds to... View more

View the conversation - Tweetchat: Manag…

Atlantis Healthcare diabetes Tweetchat

Working in partnership, Atlantis Healthcare and pharmaphorum conducted a Tweetchat focussed on the real world challenges patients face in managing... View more

Patient Opinion Leaders: Andrew Schorr


As a cancer survivor and passionate patient advocate, Andrew Schorr typifies the concept of a Patient Opinion Leader (POL). He is a contributor to the... View more

White Papers

Pricing & Market Access Outlook 2014

Pricing & Market Access Outlook 2014

Pricing and market access are key issues for the pharma industry as healthcare budgets continue to tighten and the value of innovative drugs, particularly in areas of high unmet need,... View info

Getting the most out of technology for m…

Getting the most out of technology for multichannel marketing

While every pharma company recognises the potential of multichannel marketing to optimize its engagement with prescribers, many are yet to implement it to maximum potential. IMS Health explains how a... View info

Anchoring qualitative methodologies in b…

Anchoring qualitative methodologies in business intelligence using smartphone appsPaul Mannu

The use of smartphone apps in market research enables genuine 'in the moment' insight to help us really understand behaviour. Combining this with qualitative methods gives us a deeper insight into behaviours... View info

Opportunities and challenges around non-…

Opportunities and challenges around non-adherence and self‑management in diabetesDr Sinéad NíMhurchadha and Stephen Galt

Diabetes is a chronic condition, the prevalence of which has been escalating around the world for years. The significant consequences this has for healthcare budgets and patient wellbeing is well... View info

Further News & Articles

UK experimental drugs bill 'could hit clinical trial recruitment'

Patients in England and Wales will be able to get access to experimental medicines from next March if a new b... Read more


Stem cell researchers closer to creating human organs

Researchers in the US have made functional intestinal tissue in the lab that could be used to test new drugs and... Read more


Parkinson’s charity pushes industry collaboration

Parkinson's UK has appointed pharma industry expert Dr Arthur Roach as its research director to increase coll... Read more


Regeneron's Eylea trumps rivals in NIH study

Regeneron is claiming victory after a US-government sponsored trial has suggested its eye treatment Eylea is sup... Read more


NICE swayed by long term Glivec data

NICE has reversed a long-standing block on using Glivec in GIST tumours, saying new evidence has persuaded it to... Read more


FDA facing huge pressure as Ebola worsens

The Food and Drug Administration (FDA) told the US Congress yesterday it is working hard to clarify the framewor... Read more